Solid Biosciences to Participate at Cantor's Virtual Muscular Dystrophy Symposium
Solid Biosciences to Participate at Cantor's Virtual Muscular Dystrophy Symposium
CHARLESTOWN, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, and Gabriel Brooks, M.D., Chief Medical Officer, will present at Cantor's Virtual Muscular Dystrophy Symposium on Tuesday, April 2, 2024, at 8:15 am ET.
马萨诸塞州查尔斯敦，2024年3月27日（GLOBE NEWSWIRE）——开发神经肌肉和心脏疾病精准基因药物的生命科学公司Solid Biosciences Inc.（纳斯达克股票代码：SLDB）今天宣布，总裁兼首席执行官博昆博和首席医学官加布里埃尔·布鲁克斯医学博士将于2024年4月2日星期二8点15分出席坎托虚拟肌肉萎缩症研讨会美国东部时间上午
A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for 30 days on the Events page.
演示文稿的网络直播将在公司网站 “投资者” 部分的 “活动” 页面上播出，也可以单击 这里。网络直播重播将在 “活动” 页面存档 30 天。
About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid's mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.
关于固体生物科学
Solid Biosciences是一家生命科学公司，专注于推进候选基因疗法产品组合，包括用于治疗杜兴氏肌营养不良症（杜兴纳）的 SGT-003、用于治疗儿茶酚胺能多态性心动过速（CPVT）的 SGT-501、用于治疗 BAG3 介导的扩张型心肌病的 AVB-401 以及用于治疗致命心脏病的其他资产。Solid 正在推进其针对罕见神经肌肉和心脏疾病的多元化产品线，汇集了科学、技术、疾病管理和护理领域的专家。Solid 以患者为中心，由直接受影响的人创立，其使命是改善患有这些毁灭性疾病的患者的日常生活。欲了解更多信息，请访问 www.solidbo.com。
Solid Biosciences Contact:
Leah Monteiro
VP, Investor Relations & Communications
617-766-3430
lmonteiro@solidbio.com
固体生物科学联系方式：
莉亚·蒙泰罗
投资者关系与传播副总裁
617-766-3430
lmonteiro@solidbio.com
Source: Solid Biosciences Inc.
资料来源：固态生物科学公司
译文内容由第三方软件翻译。